1. Show article details.

    Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    GlobeNewswire – 4:05 PM ET 06/01/2020

    Karyopharm Therapeutics Inc. (KPTI), an innovation-driven pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 25,800 shares of Karyopharm’s common stock to seven newly-hired employees, with a grant date of May 29, 2020.

  2. Show article details.

    Karyopharm Reports Positive Phase 3 BOSTON Data in Oral Presentation at the American Society of Clinical Oncology 2020 Virtual Scientific Program

    GlobeNewswire – 4:05 PM ET 05/28/2020

    -- Combination of Once-Weekly XPOVIO®, Once-Weekly Velcade® and Dexamethasone Prolonged Median Progression-Free Survival by 47% Compared to Standard Twice-Weekly Velcade® plus Dexamethasone -- -- SVd Was Superior to Vd Across Key Secondary Efficacy Endpoints Including Overall Response Rate, Percent of Patients Achieving ≥VGPR and Median Duration of Response -- -- SVd Was Associated with S...

  3. Show article details.

    Karyopharm to Participate at Jefferies Virtual Healthcare Conference

    GlobeNewswire – 4:05 PM ET 05/26/2020

    -- Fireside Chat Scheduled for Tuesday, June 2, 2020, at 9:30 a.m. ET -- Karyopharm Therapeutics Inc. (KPTI), an innovation-driven pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020 at 9:30 a.m. ET.

  4. Show article details.

    BRIEF-Karyopharm Announces Investor Conference Call To Discuss Phase 3 Boston Data To Be Presented At American Society Of Clinical Oncology 2020 Virtual Scientific Program

    Reuters – 7:17 AM ET 05/26/2020

    Karyopharm Therapeutics Inc (KPTI): * KARYOPHARM ANNOUNCES INVESTOR CONFERENCE CALL TO DISCUSS PHASE 3 BOSTON DATA TO BE PRESENTED AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 2020 VIRTUAL SCIENTIFIC PROGRAM Source text for Eikon: Further company coverage:

  5. Show article details.

    Karyopharm Announces Investor Conference Call to Discuss Phase 3 BOSTON Data To Be Presented at the American Society of Clinical Oncology 2020 Virtual Scientific Program

    GlobeNewswire – 7:00 AM ET 05/26/2020

    -- Conference Call Scheduled for Friday, May 29, 2020 at 1:00 p.m. ET -- Karyopharm Therapeutics Inc. (KPTI), an innovation-driven  pharmaceutical company, today announced it will host an investor conference call to discuss detailed results from the pivotal, Phase 3 BOSTON study evaluating once-weekly XPOVIO® in combination with once-weekly Velcade® and low-dose dexamethasone compared to standard...

  6. Show article details.

    Karyopharm Submits Supplemental New Drug Application to FDA for XPOVIO® (selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Line of Therapy

    GlobeNewswire – 8:00 AM ET 05/20/2020

    Karyopharm Therapeutics Inc. (KPTI), an innovation-driven  pharmaceutical company, today announced it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration seeking approval for XPOVIO®, its first-in-class, oral Selective Inhibitor of Nuclear Export compound, as a new treatment for patients with previously treated multiple myeloma.

  7. Show article details.

    Karyopharm Donates 60,000 Medical Masks Across Massachusetts and the United States in Partnership with Family Reach, Myeloma Crowd and The Leukemia & Lymphoma Society

    GlobeNewswire – 8:00 AM ET 05/13/2020

    Karyopharm Therapeutics Inc. (KPTI), an innovation-driven pharmaceutical company, today announced a new initiative to donate and distribute 60,000 medical masks to some of the most vulnerable individuals impacted by the ongoing COVID-19 pandemic including cancer patients, their families, and the healthcare workers caring for them.

  8. Show article details.

    Karyopharm to Participate at 2020 RBC Capital Markets Global Healthcare Virtual Conference

    GlobeNewswire – 7:00 AM ET 05/12/2020

    Karyopharm Therapeutics Inc. (KPTI), an innovation-driven pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will participate in a fireside chat at the 2020 RBC Capital Markets Global Healthcare Virtual Conference on Tuesday, May 19, 2020 at 8:35 a.m. ET.

  9. Show article details.

    BRIEF-Karyopharm Therapeutics Entered Amendment To Open Market Sale Agreement Dated August 17, 2018

    Reuters – 6:39 PM ET 05/05/2020

    Karyopharm Therapeutics Inc (KPTI): * Karyopharm Therapeutics Inc (KPTI) - ENTERED AMENDMENT TO OPEN MARKET SALE AGREEMENT DATED AUGUST 17, 2018. * Karyopharm Therapeutics Inc (KPTI) - MAY OFFER AND SELL SHARES HAVING ADDITIONAL OFFERING PRICE OF UP TO $100 MILLION Source text: [https://bit.ly/2A3iStK] Further company coverage:

  10. Show article details.

    BRIEF-Antengene Announced Broadened Partnership And Territory Expansion Agreement With Karyopharm

    Reuters – 8:43 AM ET 05/05/2020

    Karyopharm Therapeutics Inc (KPTI): * ANTENGENE CORPORATION - ANNOUNCED BROADENED PARTNERSHIP AND TERRITORY EXPANSION AGREEMENT WITH KARYOPHARM THERAPEUTICS. * ANTENGENE CORPORATION - AGREEMENT BROADENS CO'S RIGHTS IN ASIA PACIFIC REGION FOR XPOVIO, ELTANEXOR, VERDINEXOR & KPT-9274 Source text for Eikon: Further company coverage:

  11. Show article details.

    Antengene Announces Expansion of Partnership with Karyopharm in Asia Pacific Markets

    PR Newswire – 8:30 AM ET 05/05/2020

    SHANGHAI, May 5, 2020 Antengene Corporation today announced a broadened partnership and territory expansion agreement with Karyopharm Therapeutics Inc. (KPTI) for development and commercialization of four oral novel drugs and drug candidates to support its mission of treating patients beyond borders.

  12. Show article details.

    BRIEF-Karyopharm Therapeutics Reports Q1 Loss Per Share Of $0.78

    Reuters – 7:19 AM ET 05/05/2020

    Karyopharm Therapeutics Inc (KPTI): * KARYOPHARM REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND HIGHLIGHTS RECENT COMPANY PROGRESS. * Q1 LOSS PER SHARE $0.78. * Q1 EARNINGS PER SHARE ESTIMATE $-0.69 -- REFINITIV IBES DATA. * NET PRODUCT REVENUE FOR Q1 OF 2020 WAS $16.1 MILLION.

  13. Show article details.

    Karyopharm Reports First Quarter 2020 Financial Results and Highlights Recent Company Progress

    GlobeNewswire – 7:00 AM ET 05/05/2020

    -- Pivotal Phase 3 BOSTON Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival; Oral Presentation at ASCO 2020 Virtual Scientific Program and sNDA To Be Submitted by End of May 2020 -- -- First Quarter 2020 XPOVIO Net Product Sales of $16.1 Million and Total Revenues of $18.1 Million -- -- To Receive $12.0 Million from Antengene for Expanded Territory -- -- sNDA ...

  14. Show article details.

    Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    GlobeNewswire – 4:05 PM ET 05/01/2020

    Karyopharm Therapeutics Inc. (KPTI), an innovation-driven pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 74,800 shares of Karyopharm’s common stock to 15 newly-hired employees, with a grant date of April 30, 2020.

  15. Show article details.

    PROMETRIKA and Karyopharm: Partners in Global COVID-19 Trial

    Business Wire – 1:03 PM ET 04/30/2020

    Cambridge, MA-based clinical research organization to be responsible for Clinical Trial Site Management and On-Site Monitoring in the United States PROMETRIKA, a leading clinical research organization, is collaborating with Karyopharm Therapeutics (KPTI) to conduct the first randomized clinical trial for low-dose selinexor, an XPO1 inhibitor, in hospitalized patients with severe COVID-19.

  16. Show article details.

    Karyopharm Announces Data from Phase 3 BOSTON Study Selected for Late-Breaking Oral Presentation at the American Society of Clinical Oncology 2020 Virtual Scientific Program

    GlobeNewswire – 1:58 PM ET 04/29/2020

    - A Total of Five Abstracts Selected for Presentation, Including Two Highlighting Data from the Darzalex® and Kyprolis® Arms of the Phase 1b/2 STOMP Study - Karyopharm Therapeutics Inc. (KPTI), an innovation-driven  pharmaceutical company, today announced that its late-breaking abstract detailing results from the pivotal, Phase 3 BOSTON study has been selected for oral presentation at the upcoming ...

  17. Show article details.

    Karyopharm to Report First Quarter 2020 Financial Results on May 5, 2020

    GlobeNewswire – 4:05 PM ET 04/28/2020

    -- Conference Call Scheduled for Tuesday, May 5, 2020, at 8:30 a.m. ET -- Karyopharm Therapeutics Inc. (KPTI) today announced that it will report first quarter 2020 financial results on Tuesday, May 5, 2020. To access the conference call, please dial  437-4406 or  756-4292 at least 10 minutes prior to the start time and refer to conference ID 9936655.

  18. Show article details.

    Precision For Medicine Partners With Karyopharm Therapeutics To Initiate New Global Clinical Trial To Treat Patients With COVID-19

    PR Newswire – 9:08 AM ET 04/22/2020

    BUDAPEST, Hungary, April 22, 2020  Precision for Medicine, a pioneer in the design, development and execution of biomarker-informed clinical studies and complex data management, is collaborating with Karyopharm Therapeutics (KPTI) to help conduct the first global randomized clinical trial for low dose selinexor, an XPO1 inhibitor, in hospitalized patients with severe COVID-19.

  19. Show article details.

    BRIEF-Karyopharm Announces Dosing Of First Patient In Randomized Study Evaluating Low Dose Selinexor In Patients With Severe Covid-19

    Reuters – 9:01 AM ET 04/20/2020

    Karyopharm Therapeutics Inc (KPTI): * KARYOPHARM ANNOUNCES DOSING OF FIRST PATIENT IN RANDOMIZED STUDY EVALUATING LOW DOSE SELINEXOR IN PATIENTS WITH SEVERE COVID-19 Source text for Eikon: Further company coverage:

  20. Show article details.

    Karyopharm Announces Dosing of First Patient in Randomized Study Evaluating Low Dose Selinexor in Patients with Severe COVID-19

    GlobeNewswire – 7:00 AM ET 04/20/2020

    Karyopharm Therapeutics Inc. (KPTI) today announced dosing of the first patient in a randomized Phase 2 clinical study evaluating low dose oral selinexor in hospitalized patients with severe COVID-19. The randomized, multi-center, placebo-controlled Phase 2 study of low dose selinexor is designed to assess the activity and safety of 20mg of selinexor given orally three times a week for two weeks.

Page:

Today's and Upcoming Events

  • Aug
    04

    KPTI to announce Q2 earnings (Unconfirmed)

Past Events (last 90 days)

  • May
    05

    KPTI announced Q1 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.